Airbus Développement has decided to support BioMAdvanced Diagnostics through financial aid on one hand, and on the other hand by making it benefit from services that Airbus Développement will deem appropriate for the development of its project.
📌One decisive criterion for this partnership has been the track record of BioMAdvanced Diagnostics in creating highly qualified jobs (9 in 18 months) and its potential to create more in the near future.
Airbus Développement main activity is to participate in local economic development around the sites of Airbus and its subsidiaries through direct aid to companies and, in this way, to stimulate and facilitate the creation of jobs.
“We thank Airbus Développement infinitely for their trust, which drives us to move ever further towards the marketing of our innovative diagnostic tests!” Frédéric Pette, CEO BioMAdvanced Diagnostics.
About BioMAdvanced Diagnostics
BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, spinoff from the CR2TI (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – Nantes University) and from the University Hospital (CHU) of Nantes.
BioMAdvanced Diagnostics brings a real disruption in the field of Biomarkers related to the Immune System based on 20 years of academic translational research. Its main goal is to enable a truly personalized, preventive and predictive medicine which will greatly improve outcomes for the patient by providing unprecedented tools to clinicians.
The first applications will concern the improvement of kidney or lungs transplanted patients’ follow up. Two key benefits of its solutions : minimally invasive solutions for the patient and very substantial cost reductions for the Health Systems.